| Date | Title | Description |
| 14.03.2025 | Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing | Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the p... |
| 13.03.2024 | PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune® | - |
| 24.04.2023 | PDS Biotech Receives $1.4 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program | - |
| 24.08.2022 | PDS Biotech Completes $35 Million Financing Agreement Led By Horizon Technology Finance | Initial tranche of $25 million provides funding in preparation for registrational trial for lead candidate PDS0101Conference call scheduled for Thursday, August 25, 2022 at 8:00 AM EDT
FLORHAM PARK, N.J., Aug. 24, 2022 (GLOBE NEWSWIRE) -- P... |
| 19.04.2022 | PDS Biotech Receives $1.2 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program | FLORHAM PARK, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease ... |
| 02.02.2022 | PDS Biotech Announces Preliminary Efficacy Achievement in VERSATILE-002 Phase 2 Trial of PDS0101 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Head and Neck Cancer | FLORHAM PARK, N.J., Feb. 02, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary ... |
| 02.02.2022 | PDS Biotechnology : Biotech Announces Preliminary Efficacy Achievement in VERSATILE-002 Phase 2 Trial of 0101 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Head and Neck Cancer - Form 8-K | PDS Biotech Announces Preliminary Efficacy Achievement in VERSATILE-002 Phase 2 Trial of PDS0101 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Head and Neck Cancer
Achievement of initial efficacy milestone allows full enrollment... |
| 06.12.2021 | NetScientific : PDS Phase 2 Clinical Trial Update | NetScientific plc
("NetScientific", the "Group" or the "Company")
PDS Phase 2 Clinical Trial Update
PDS Biotech Provides Recruitment update for National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Ba... |
| 01.11.2021 | PDS to License Novel Proteins for Flu Vaccine | NetScientific plc
("NetScientific", the "Group" or the "Company")
PDS to License Novel Proteins for Flu Vaccine
PDS Biotech Announces Agreement with University of Georgia to License Novel Proteins for Versamune... |
| 06.10.2021 | PDS Biotechnology : Biotech Enrolls First Stage of Checkpoint Inhibitor Naïve Patient Arm of Phase 2 Clinical Trial in Advanced HPV-16 Positive Head and Neck Cancer (Form 8-K) | PDS Biotech Enrolls First Stage of Checkpoint Inhibitor Naïve Patient Arm of Phase 2 Clinical Trial in Advanced HPV-16 Positive Head and Neck Cancer
Florham Park, NJ, October 4, 2021 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinica... |
| 05.10.2021 | NetScientific : PDS Phase 2 Clinical Trial Update | NetScientific plc
("NetScientific", the "Group" or the "Company")
PDS Phase 2 Clinical Trial Update
PDS Biotech Enrolls First Stage of Checkpoint Inhibitor Naïve Patient Arm of Phase 2 Clinical Trial in Advance... |
| 04.10.2021 | PDS Biotechnology : Biotech Enrolls First Stage of Checkpoint Inhibitor Naïve Patient Arm of Phase 2 Clinical Trial in Advanced HPV-16 Positive Head and Neck Cancer | FLORHAM PARK, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating tec... |
| 20.09.2021 | PDS Biotech Achieves Safety Requirement Milestone For the First 12 Patients in the VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Advanced Head and Neck Cancer | FLORHAM PARK, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating te... |
| 20.09.2021 | PDS Biotechnology : Biotech Achieves Safety Requirement Milestone For the First 12 Patients in the VERSATILE-002 Phase 2 Combination Trial of 0101-KEYTRUDA® in Advanced Head and Neck Cancer (Form 8-K)... | PDS Biotech Achieves Safety Requirement Milestone For the First 12 Patients in the VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Advanced Head and Neck Cancer
No dose limiting toxicities observed in initial group of 12 pat... |
| 09.09.2021 | PDS Biotechnology : Biotech Completes Enrollment of Lead-In Safety Cohort in VERSATILE-002 Phase 2 Combination Trial of 0101-KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer | FLORHAM PARK, N.J., Sept. 09, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating te... |
| 09.09.2021 | PDS Biotechnology : Biotech Completes Enrollment of Lead-In Safety Cohort in VERSATILE-002 Phase 2 Combination Trial of 0101-KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer (Form 8-K) | PDS Biotech Completes Enrollment of Lead-In Safety Cohort in VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
Florham Park, NJ, September 9, 2021 - PDS Biotechnology Corporation (N... |
| 17.06.2021 | PDS BIOTECHNOLOGY CORPORATION
PDS Biotechnology Corporation Announces Closing of Approximately $52 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares | FLORHAM PARK, N.J., June 17, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotechnology" or the "Company"), a clinical-stage immunotherapy company developing a pipeline of novel cancer ther... |
| 14.06.2021 | PDS BIOTECHNOLOGY CORPORATION
PDS Biotechnology : Announces Oncology Research and Development Day | FLORHAM PARK, N.J., June 14, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage cancer immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activat... |
| 08.06.2021 | PDS BIOTECHNOLOGY CORPORATION
CORRECTING AND REPLACING -- PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study in Oral Presentation at ASCO 2021 Annual Meeting | FLORHAM PARK, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by PDS Biotechnology Corporation (Nasdaq: PDSB), we've been informed by the company, the beginning of the conference call paragr... |
| 08.06.2021 | PDS BIOTECHNOLOGY CORPORATION
PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study in Oral Presentation at ASCO 2021 Annual Meeting | FLORHAM PARK, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating tec... |
| 03.06.2021 | PDS BIOTECHNOLOGY CORPORATION
PDS Biotechnology : Expands VERSATILE-002 study of PDS0101 and KEYTRUDA® in Advanced Head and Neck Cancer to Include Patients Who Have Failed Prior Treatment with Checkp... | PDS Biotechnology Expands VERSATILE-002 study of PDS0101 and KEYTRUDA®
in Advanced Head and Neck Cancer to Include Patients Who Have Failed Prior
Treatment with Checkpoint Inhibitors
Florham Park, NJ, June 3, 2021 - PDS Biotechnology Corpor... |
| 24.05.2021 | PDS BIOTECHNOLOGY CORPORATION
PDS Biotech to Host Company Conference Call Following Oral Presentation of PDS0101 Data at 2021 ASCO Annual Meeting | FLORHAM PARK, N.J., May 24, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating tech... |
| 17.05.2021 | PDS BIOTECHNOLOGY CORPORATION
PDS Biotechnology : Biotech Receives $4.5M After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program | FLORHAM PARK, N.J., May 17, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary V... |
| 11.03.2021 | PDS Biotech Announces that its COVID-19 Vaccine Consortium Received a Commitment from The Ministry of Science, Technology and Innovation of Brazil (MCTI) to fund Clinical Development and Commercializa... | FLORHAM PARK, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on PDS Biotech’s proprietary... |
| 20.08.2012 | Amid preclinical-clinical transition, cancer vaccine firm CEO talks business, licensing & science | FB: At the time we were very early stage and actively looking for funding. We had a couple of VC offers, but our board wasn’t too interested in those deals because of the dilution of equity. I think they wanted us to create more value befor... |
| - | Amid preclinical-clinical transition, cancer vaccine firm CEO talks business, licensing & science | With preclinical studies and a new licensing deal under its belt, immunotherapy drug developer PDS Biotechnology is getting its manufacturing plans in place and preparing to file an IND in next month or two so it can begin clinical trials o... |
